NCT03478514 2026-04-09
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
Alliance Foundation Trials, LLC.
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT04234061 2024-11-07
TARMAC
Peter MacCallum Cancer Centre, Australia
Phase 2 Active not recruiting
NCT02332980 2024-01-03
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Mayo Clinic
Phase 2 Completed
NCT04665115 2022-08-03
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
Academic and Community Cancer Research United
Phase 2 Withdrawn
NCT01109069 2020-05-27
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Pharmacyclics LLC.
Phase 2 Completed
NCT01980628 2019-10-16
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Pharmacyclics LLC.
Phase 2 Completed
NCT01980654 2019-04-16
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
Pharmacyclics LLC.
Phase 2 Completed
NCT02272686 2018-12-05
Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01325701 2017-03-31
Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Pharmacyclics LLC.
Phase 2 Completed
NCT02670317 2017-03-20
FIL-GALILEO
Fondazione Italiana Linfomi - ETS
Phase 2 Terminated